Allot Communications (ALLT) Tops Q2 EPS by 2c, Slight Beat on Revenues; Offers FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to Allot Communications (ALLT) Tops Q2 EPS by 2c, Slight Beat on Revenues; Offers FY18 Revenue Outlook

Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...)

August 6, 2018 9:27 AM EDT

Today's Pre-Open Movers

Ovid Therapeutics Inc. (NASDAQ: OVID) 27% LOWER; announced that the Phase 2 STARS trial of OV101 achieved its primary endpoint of safety and tolerability. The investigational medicine showed a favorable safety profile and was well tolerated in adults and adolescents with Angelman syndrome. OV101 is the only selective extrasynaptic GABAA receptor agonist in development shown to mediate tonic inhibition, a key underlying pathophysiological mechanism of Angelman syndrome. Ovids founder, president and chief scientific officer, Matthew During, M.D., DSc, FACP, will present the data today at the 2018 Angelman Syndrome... More

Needham & Company Upgrades Allot Communications (ALLT) to Buy

August 6, 2018 5:46 AM EDT

Needham & Company upgraded Allot Communications (NASDAQ: ALLT) from Hold to Buy with a price target of $6.35.

Analyst Alex Henderson says a new tier 1 win is a major proof-point on Intensifying SaaS business. The analyst says management continues to executed against a turn-around... More